|1.||Kamps, Jan A A M: 1 article (01/2002)|
|2.||Scherphof, Gerrit L: 1 article (01/2002)|
|3.||Koning, Gerben A: 1 article (01/2002)|
|4.||Allen, T M: 1 article (09/2001)|
|5.||Scherphof, G L: 1 article (09/2001)|
|6.||Koning, G A: 1 article (09/2001)|
|7.||Zalipsky, S: 1 article (09/2001)|
|8.||Kamps, J A: 1 article (09/2001)|
|9.||Morselt, H W: 1 article (09/2001)|
|10.||Gorter, A: 1 article (09/2001)|
08/20/1999 - "Based on these observations, we tentatively conclude that during the interaction of the immunoliposomes with the tumor cells the lipophilic prodrug FUdR-dP is selectively transferred to the cell surface and subsequently internalized by constitutive endocytic or pinocytic invaginations of the plasma membrane, thus ultimately delivering the prodrug to a lysosomal compartment where hydrolysis and release of parent drug takes place. "
09/01/2001 - "Although with a long-circulating immunoliposome formulation, efficiently retaining the prodrug FUdR-dP, we achieved enhanced uptake by hepatic metastases, this was probably not mediated by specific interaction with the tumor cells, but rather by tumor-associated macrophages."
01/01/2002 - "A monoclonal antibody against the rat colon carcinoma CC531 was covalently coupled to liposomes containing a dipalmitoylated derivative of the anti-cancer drug FUdR (FUdR-dP) as a prodrug in their bilayers. "
|2.||Neoplasm Metastasis (Metastasis)
|3.||Colonic Neoplasms (Colon Cancer)